Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Endovascular Treatment Devices Market by Product (Percutaneous endovascular aneurysm repair (EVAR), Fenestrated EVAR, Aortic stents Biodegradable Stents, Self-expanding Nitinol Stents, Thoracic aortic aneurysms grafts, Other Devices), by Procedure (Balloon Angioplasty, Angioplasty with Stent Placement, Drug-Eluting Stents (DES) Renal Artery Angioplasty and Stenting Carotid Artery Stenting Transfemoral Carotid Artery Stenting Transcarotid Artery Revascularization Intravascular Brachytherapy, Thrombolysis, Renal Artery Angioplasty and Stenting, Transfemoral Carotid Artery Stenting, Transcarotid Artery Revascularization, Intravascular Brachytherapy, Carotid Artery Stenting), by Appication (Pulmonary, Vascular, Cardiology Surgery, Neurology, Radiology) and by End User (Hospitals, Ambulatory Surgical Center, Clinics): Global Opportunity Analysis and Industry Forecast, 2023-2032

A10947

Pages: NA

Charts: NA

Tables: NA

Endovascular surgical procedure is a minimally invasive and an innovative procedure utilized in the treatment of various medical conditions that affect the blood vessels such as aneurysm that causes ballooning or swelling of the blood vessels. The procedure initiates by making an incision on the body to gain access to the blood vessels. Further a flexible, plastic tube, stents or catheter is inserted into the affected blood vessel to permit withdrawal or delivery of medication from patient’s bloodstream. These endovascular treatment devices are used for several therapies such as intravenous antibiotic treatment, long-term intravenous feeding, chemotherapy and blood transfusions. In few instances, the endovascular repair doesn’t work for patients, especially when the aneurysm is located very close to aorta or the arteries or when it is very narrow to allow passage of the catheter in surgical procedure. In such cases, people generally opt for traditional open surgery.

COVID – 19 scenario analysis: 

  • The COVID-19 pandemic has emerged as a humanitarian as well as economic crisis, creating strain on the society and affecting millions of people and businesses
  • Industry closures and people are asked to stay in their homes which has cause taken a huge toll in terms of money and economic growth
  • Over 4 million people affected globally, with 300 thousand losing their lives due to SARS-CoV-2
  • Healthcare organizations are already working in battle mode, preparing new plans to respond growing COVID-19 patients, right from sourcing rapid diagnosing kits to sufficient PPE kits for workers
  • Due to diversion of medical field towards treating COVID-19, the funding to R&D activities related to endovascular treatment has been reduced and this segment have to face negligence subsequently causing negative impact on endovascular treatment devices market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The endovascular treatment devices market is driven by myriad of factors such as growing geriatric population, rising prevalence of cardiovascular disorders, highly advanced endovascular therapeutics, and increasing healthcare expenditure. The rising number of patients suffering with aortic aneurysms and ischemic heart strokes, worldwide will augment the demand for endovascular treatment devices in the market. Industry demands and patient preference towards minimally-invasive therapies and diagnostics would further surge the market growth.

The rising expenditure on healthcare sector is catalyzing the research and developments and novel product launches in endovascular therapy devices has resulted into increasing adoption of these devices. Organization for Economic Co-operation and Development (OECD) survey report, stated in 2018 average per capita health expenditure in the U.S. was about USD 10,586. Current research and development activities have laid emphasis on development of safer and highly efficient endovascular therapy devices to prevent large-caliber femoral arteriotomies. With growing popularity and acceptance of percutaneous endovascular aneurysm repair and transcatheter aortic valve repair, there will be immense growth pockets for the key market players to develop and produce endovascular therapy devices with better efficiency in future.

Several medical complexities involving strokes, and other cardiovascular disease and the need for treatment from inside the blood vessels, and the endovascular devices offering minimally invasive therapy attributed with further shorter recovery time, and reduced stay at healthcare facilities would further fuel the endovascular therapy devices market.

On the contrary, high costs related to endovascular surgeries, lack of well-developed infrastructure in economically poor geographies and lack of skilled surgeons to operate endovascular devices and conduct surgeries are the factors impeding the market growth.

Rising adoption of endovascular treatment devices in ischemic strokes to stimulate market expansion

The rising adoption of endovascular surgeries for treatment acute ischemic strokes coupled with immense clinical is fuelling the growth of the endovascular treatment devices market. Stroke remains a major factor resulting in high morbidity and mortality globally, with affecting almost 800,000 individuals in the U.S. alone. Ischemic strokes dominate the occurrence of strokes accounting for almost 85%. As a result, the rising need for novel therapeutic devices for ischemic stroke treatment by reducing intracranial aneurysms would propel the demand for endovascular devices. Thus in the past few years, the global endovascular treatment devices market has shown significant growth with increasing prevalence of ischemic strokes and growing acceptance of endovascular treatment devices.

Increase in prevalence of cardiovascular diseases to amplify growth

Cardiovascular diseases hold the first place in cause for death globally than any other disease according to World Health Organization (WHO). In 2016, cardiac diseases caused fatality in an estimated 17.9 million people, highlighting 31% of all global deaths with majority deaths were accounted in developing economies with low income. This can be an opportunity to the endovascular treatment devices to expand into developing economies.

Cardiac diseases are increasing with rising population and changing lifestyle. According to the Centers for Disease Control, the number of deaths due to cardiac diseases in United States is more than 606,000 on yearly basis. Four out of five CVD deaths are due to heart attacks and strokes. According to the World Journal of Cardiovascular Diseases, more than 7 million deaths are due to the sudden cardiac arrest worldwide every year. Thus, the growing cases of heart failures, and other heart-related conditions are facilitating the endovascular treatment devices market growth.

Key benefits of the report:

  • This study presents the analytical depiction of the global endovascular treatment devices industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global endovascular treatment devices market share.
  • The current market is quantitatively analyzed to highlight the global endovascular treatment devices market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global endovascular treatment devices market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Endovascular treatment devices Market research report:

  • What are the leading market players active in the endovascular treatment devices market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Key Market Segments

  • By Product
    • Percutaneous endovascular aneurysm repair (EVAR)
    • Fenestrated EVAR
    • Aortic stents Biodegradable Stents
    • Self-expanding Nitinol Stents
    • Thoracic aortic aneurysms grafts
    • Other Devices
  • By Procedure
    • Balloon Angioplasty
    • Angioplasty with Stent Placement
    • Drug-Eluting Stents (DES) Renal Artery Angioplasty and Stenting Carotid Artery Stenting Transfemoral Carotid Artery Stenting Transcarotid Artery Revascularization Intravascular Brachytherapy
    • Thrombolysis
    • Renal Artery Angioplasty and Stenting
    • Transfemoral Carotid Artery Stenting
    • Transcarotid Artery Revascularization
    • Intravascular Brachytherapy
    • Carotid Artery Stenting
  • By Appication
    • Pulmonary
    • Vascular
    • Cardiology Surgery
    • Neurology
    • Radiology
  • By End User
    • Hospitals
    • Ambulatory Surgical Center
    • Clinics
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Lombard Medical Technologies
  • Terumo Corporation.
  • InspireMD
  • Penumbra
  • Boston Scientific Corporation
  • Endospan
  • Medtronic plc
  • Getinge AB
  • Japan Lifeline
  • Cardinal Health


3

  • B.braun
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ENDOVASCULAR TREATMENT DEVICES MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Percutaneous Endovascular Aneurysm Repair (EVAR)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Fenestrated EVAR

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Aortic Stents Biodegradable Stents

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Self-expanding Nitinol Stents

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Thoracic Aortic Aneurysms Grafts

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Other Devices

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: ENDOVASCULAR TREATMENT DEVICES MARKET, BY PROCEDURE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Procedure

    • 5.2. Balloon Angioplasty

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Angioplasty With Stent Placement

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Drug-Eluting Stents (DES) Renal Artery Angioplasty And Stenting Carotid Artery Stenting Transfemoral Carotid Artery Stenting Transcarotid Artery Revascularization Intravascular Brachytherapy

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Thrombolysis

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Renal Artery Angioplasty And Stenting

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Transfemoral Carotid Artery Stenting

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Transcarotid Artery Revascularization

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

    • 5.9. Intravascular Brachytherapy

      • 5.9.1. Key Market Trends, Growth Factors and Opportunities

      • 5.9.2. Market Size and Forecast, By Region

      • 5.9.3. Market Share Analysis, By Country

    • 5.10. Carotid Artery Stenting

      • 5.10.1. Key Market Trends, Growth Factors and Opportunities

      • 5.10.2. Market Size and Forecast, By Region

      • 5.10.3. Market Share Analysis, By Country

  • CHAPTER 6: ENDOVASCULAR TREATMENT DEVICES MARKET, BY APPICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Appication

    • 6.2. Pulmonary

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Vascular

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Cardiology Surgery

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Neurology

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Radiology

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: ENDOVASCULAR TREATMENT DEVICES MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Ambulatory Surgical Center

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Clinics

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: ENDOVASCULAR TREATMENT DEVICES MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Procedure

      • 8.2.4. Market Size and Forecast, By Appication

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Endovascular Treatment Devices Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Procedure
        • 8.2.7.3. Market Size and Forecast, By Appication
        • 8.2.7.4. Market Size and Forecast, By End User
      • 8.2.8. Canada Endovascular Treatment Devices Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Procedure
        • 8.2.8.3. Market Size and Forecast, By Appication
        • 8.2.8.4. Market Size and Forecast, By End User
      • 8.2.9. Mexico Endovascular Treatment Devices Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Procedure
        • 8.2.9.3. Market Size and Forecast, By Appication
        • 8.2.9.4. Market Size and Forecast, By End User
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Procedure

      • 8.3.4. Market Size and Forecast, By Appication

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Endovascular Treatment Devices Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Procedure
        • 8.3.7.3. Market Size and Forecast, By Appication
        • 8.3.7.4. Market Size and Forecast, By End User
      • 8.3.8. Germany Endovascular Treatment Devices Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Procedure
        • 8.3.8.3. Market Size and Forecast, By Appication
        • 8.3.8.4. Market Size and Forecast, By End User
      • 8.3.9. Italy Endovascular Treatment Devices Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Procedure
        • 8.3.9.3. Market Size and Forecast, By Appication
        • 8.3.9.4. Market Size and Forecast, By End User
      • 8.3.10. Spain Endovascular Treatment Devices Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Procedure
        • 8.3.10.3. Market Size and Forecast, By Appication
        • 8.3.10.4. Market Size and Forecast, By End User
      • 8.3.11. UK Endovascular Treatment Devices Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Procedure
        • 8.3.11.3. Market Size and Forecast, By Appication
        • 8.3.11.4. Market Size and Forecast, By End User
      • 8.3.12. Russia Endovascular Treatment Devices Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Procedure
        • 8.3.12.3. Market Size and Forecast, By Appication
        • 8.3.12.4. Market Size and Forecast, By End User
      • 8.3.13. Rest Of Europe Endovascular Treatment Devices Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Procedure
        • 8.3.13.3. Market Size and Forecast, By Appication
        • 8.3.13.4. Market Size and Forecast, By End User
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Procedure

      • 8.4.4. Market Size and Forecast, By Appication

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Endovascular Treatment Devices Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Procedure
        • 8.4.7.3. Market Size and Forecast, By Appication
        • 8.4.7.4. Market Size and Forecast, By End User
      • 8.4.8. Japan Endovascular Treatment Devices Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Procedure
        • 8.4.8.3. Market Size and Forecast, By Appication
        • 8.4.8.4. Market Size and Forecast, By End User
      • 8.4.9. India Endovascular Treatment Devices Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Procedure
        • 8.4.9.3. Market Size and Forecast, By Appication
        • 8.4.9.4. Market Size and Forecast, By End User
      • 8.4.10. South Korea Endovascular Treatment Devices Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Procedure
        • 8.4.10.3. Market Size and Forecast, By Appication
        • 8.4.10.4. Market Size and Forecast, By End User
      • 8.4.11. Australia Endovascular Treatment Devices Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Procedure
        • 8.4.11.3. Market Size and Forecast, By Appication
        • 8.4.11.4. Market Size and Forecast, By End User
      • 8.4.12. Thailand Endovascular Treatment Devices Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Procedure
        • 8.4.12.3. Market Size and Forecast, By Appication
        • 8.4.12.4. Market Size and Forecast, By End User
      • 8.4.13. Malaysia Endovascular Treatment Devices Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Procedure
        • 8.4.13.3. Market Size and Forecast, By Appication
        • 8.4.13.4. Market Size and Forecast, By End User
      • 8.4.14. Indonesia Endovascular Treatment Devices Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Procedure
        • 8.4.14.3. Market Size and Forecast, By Appication
        • 8.4.14.4. Market Size and Forecast, By End User
      • 8.4.15. Rest of Asia Pacific Endovascular Treatment Devices Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Procedure
        • 8.4.15.3. Market Size and Forecast, By Appication
        • 8.4.15.4. Market Size and Forecast, By End User
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Procedure

      • 8.5.4. Market Size and Forecast, By Appication

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Endovascular Treatment Devices Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Procedure
        • 8.5.7.3. Market Size and Forecast, By Appication
        • 8.5.7.4. Market Size and Forecast, By End User
      • 8.5.8. South Africa Endovascular Treatment Devices Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Procedure
        • 8.5.8.3. Market Size and Forecast, By Appication
        • 8.5.8.4. Market Size and Forecast, By End User
      • 8.5.9. Saudi Arabia Endovascular Treatment Devices Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Procedure
        • 8.5.9.3. Market Size and Forecast, By Appication
        • 8.5.9.4. Market Size and Forecast, By End User
      • 8.5.10. UAE Endovascular Treatment Devices Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Procedure
        • 8.5.10.3. Market Size and Forecast, By Appication
        • 8.5.10.4. Market Size and Forecast, By End User
      • 8.5.11. Argentina Endovascular Treatment Devices Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Procedure
        • 8.5.11.3. Market Size and Forecast, By Appication
        • 8.5.11.4. Market Size and Forecast, By End User
      • 8.5.12. Rest of LAMEA Endovascular Treatment Devices Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Procedure
        • 8.5.12.3. Market Size and Forecast, By Appication
        • 8.5.12.4. Market Size and Forecast, By End User
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning, 2024

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Cardinal Health

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Endospan

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Getinge AB

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Boston Scientific Corporation

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. InspireMD

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Japan Lifeline

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Medtronic Plc

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Lombard Medical Technologies

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Penumbra

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Terumo Corporation.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR PERCUTANEOUS ENDOVASCULAR ANEURYSM REPAIR (EVAR), BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR FENESTRATED EVAR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR AORTIC STENTS BIODEGRADABLE STENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR SELF-EXPANDING NITINOL STENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR THORACIC AORTIC ANEURYSMS GRAFTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR OTHER DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR BALLOON ANGIOPLASTY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR ANGIOPLASTY WITH STENT PLACEMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR DRUG-ELUTING STENTS (DES) RENAL ARTERY ANGIOPLASTY AND STENTING CAROTID ARTERY STENTING TRANSFEMORAL CAROTID ARTERY STENTING TRANSCAROTID ARTERY REVASCULARIZATION INTRAVASCULAR BRACHYTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR THROMBOLYSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR RENAL ARTERY ANGIOPLASTY AND STENTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR TRANSFEMORAL CAROTID ARTERY STENTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR TRANSCAROTID ARTERY REVASCULARIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR INTRAVASCULAR BRACHYTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR CAROTID ARTERY STENTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR PULMONARY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR VASCULAR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR CARDIOLOGY SURGERY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR NEUROLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR RADIOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 26. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR AMBULATORY SURGICAL CENTER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 27. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 28. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 29. NORTH AMERICA ENDOVASCULAR TREATMENT DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. NORTH AMERICA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. NORTH AMERICA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 32. NORTH AMERICA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 33. NORTH AMERICA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. U.S. ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. U.S. ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 36. U.S. ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 37. U.S. ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. CANADA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 39. CANADA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 40. CANADA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 41. CANADA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. MEXICO ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 43. MEXICO ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 44. MEXICO ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 45. MEXICO ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. EUROPE ENDOVASCULAR TREATMENT DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 47. EUROPE ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 48. EUROPE ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 49. EUROPE ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 50. EUROPE ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. FRANCE ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. FRANCE ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 53. FRANCE ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 54. FRANCE ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. GERMANY ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. GERMANY ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 57. GERMANY ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 58. GERMANY ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. ITALY ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. ITALY ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 61. ITALY ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 62. ITALY ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. SPAIN ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 64. SPAIN ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 65. SPAIN ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 66. SPAIN ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. UK ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 68. UK ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 69. UK ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 70. UK ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. RUSSIA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. RUSSIA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 73. RUSSIA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 74. RUSSIA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. REST OF EUROPE ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 76. REST OF EUROPE ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 77. REST OF EUROPE ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 78. REST OF EUROPE ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. ASIA-PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 80. ASIA-PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 81. ASIA-PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 82. ASIA-PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 83. ASIA-PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 84. CHINA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 85. CHINA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 86. CHINA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 87. CHINA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 88. JAPAN ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 89. JAPAN ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 90. JAPAN ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 91. JAPAN ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. INDIA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 93. INDIA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 94. INDIA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 95. INDIA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. SOUTH KOREA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 97. SOUTH KOREA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 98. SOUTH KOREA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 99. SOUTH KOREA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 100. AUSTRALIA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 101. AUSTRALIA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 102. AUSTRALIA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 103. AUSTRALIA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. THAILAND ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 105. THAILAND ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 106. THAILAND ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 107. THAILAND ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. MALAYSIA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 109. MALAYSIA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 110. MALAYSIA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 111. MALAYSIA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 112. INDONESIA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 113. INDONESIA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 114. INDONESIA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 115. INDONESIA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 116. REST OF ASIA PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 117. REST OF ASIA PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 118. REST OF ASIA PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 119. REST OF ASIA PACIFIC ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 120. LAMEA ENDOVASCULAR TREATMENT DEVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 121. LAMEA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 122. LAMEA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 123. LAMEA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 124. LAMEA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 125. BRAZIL ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 126. BRAZIL ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 127. BRAZIL ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 128. BRAZIL ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 129. SOUTH AFRICA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 130. SOUTH AFRICA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 131. SOUTH AFRICA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 132. SOUTH AFRICA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 133. SAUDI ARABIA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 134. SAUDI ARABIA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 135. SAUDI ARABIA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 136. SAUDI ARABIA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 137. UAE ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 138. UAE ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 139. UAE ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 140. UAE ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 141. ARGENTINA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 142. ARGENTINA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 143. ARGENTINA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 144. ARGENTINA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 145. REST OF LAMEA ENDOVASCULAR TREATMENT DEVICES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 146. REST OF LAMEA ENDOVASCULAR TREATMENT DEVICES, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 147. REST OF LAMEA ENDOVASCULAR TREATMENT DEVICES, BY APPICATION, 2025-2033 ($MILLION)
  • TABLE 148. REST OF LAMEA ENDOVASCULAR TREATMENT DEVICES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 149. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 150. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 151. CARDINAL HEALTH: OPERATING SEGMENTS
  • TABLE 152. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 153. CARDINAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154. ENDOSPAN: KEY EXECUTIVES
  • TABLE 155. ENDOSPAN: COMPANY SNAPSHOT
  • TABLE 156. ENDOSPAN: OPERATING SEGMENTS
  • TABLE 157. ENDOSPAN: PRODUCT PORTFOLIO
  • TABLE 158. ENDOSPAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 159. GETINGE AB: KEY EXECUTIVES
  • TABLE 160. GETINGE AB: COMPANY SNAPSHOT
  • TABLE 161. GETINGE AB: OPERATING SEGMENTS
  • TABLE 162. GETINGE AB: PRODUCT PORTFOLIO
  • TABLE 163. GETINGE AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 164. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 165. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 166. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 167. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 168. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 169. INSPIREMD: KEY EXECUTIVES
  • TABLE 170. INSPIREMD: COMPANY SNAPSHOT
  • TABLE 171. INSPIREMD: OPERATING SEGMENTS
  • TABLE 172. INSPIREMD: PRODUCT PORTFOLIO
  • TABLE 173. INSPIREMD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 174. JAPAN LIFELINE: KEY EXECUTIVES
  • TABLE 175. JAPAN LIFELINE: COMPANY SNAPSHOT
  • TABLE 176. JAPAN LIFELINE: OPERATING SEGMENTS
  • TABLE 177. JAPAN LIFELINE: PRODUCT PORTFOLIO
  • TABLE 178. JAPAN LIFELINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 179. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 180. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 181. MEDTRONIC PLC: OPERATING SEGMENTS
  • TABLE 182. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 183. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 184. LOMBARD MEDICAL TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 185. LOMBARD MEDICAL TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 186. LOMBARD MEDICAL TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 187. LOMBARD MEDICAL TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 188. LOMBARD MEDICAL TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 189. PENUMBRA: KEY EXECUTIVES
  • TABLE 190. PENUMBRA: COMPANY SNAPSHOT
  • TABLE 191. PENUMBRA: OPERATING SEGMENTS
  • TABLE 192. PENUMBRA: PRODUCT PORTFOLIO
  • TABLE 193. PENUMBRA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 194. TERUMO CORPORATION.: KEY EXECUTIVES
  • TABLE 195. TERUMO CORPORATION.: COMPANY SNAPSHOT
  • TABLE 196. TERUMO CORPORATION.: OPERATING SEGMENTS
  • TABLE 197. TERUMO CORPORATION.: PRODUCT PORTFOLIO
  • TABLE 198. TERUMO CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ENDOVASCULAR TREATMENT DEVICES MARKET
  • FIGURE 3. SEGMENTATION ENDOVASCULAR TREATMENT DEVICES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ENDOVASCULAR TREATMENT DEVICES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALENDOVASCULAR TREATMENT DEVICES MARKET
  • FIGURE 11. ENDOVASCULAR TREATMENT DEVICES MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. ENDOVASCULAR TREATMENT DEVICES MARKET FOR PERCUTANEOUS ENDOVASCULAR ANEURYSM REPAIR (EVAR), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ENDOVASCULAR TREATMENT DEVICES MARKET FOR FENESTRATED EVAR, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ENDOVASCULAR TREATMENT DEVICES MARKET FOR AORTIC STENTS BIODEGRADABLE STENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ENDOVASCULAR TREATMENT DEVICES MARKET FOR SELF-EXPANDING NITINOL STENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ENDOVASCULAR TREATMENT DEVICES MARKET FOR THORACIC AORTIC ANEURYSMS GRAFTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. ENDOVASCULAR TREATMENT DEVICES MARKET FOR OTHER DEVICES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ENDOVASCULAR TREATMENT DEVICES MARKET SEGMENTATION, BY BY PROCEDURE
  • FIGURE 19. ENDOVASCULAR TREATMENT DEVICES MARKET FOR BALLOON ANGIOPLASTY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. ENDOVASCULAR TREATMENT DEVICES MARKET FOR ANGIOPLASTY WITH STENT PLACEMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. ENDOVASCULAR TREATMENT DEVICES MARKET FOR DRUG-ELUTING STENTS (DES) RENAL ARTERY ANGIOPLASTY AND STENTING CAROTID ARTERY STENTING TRANSFEMORAL CAROTID ARTERY STENTING TRANSCAROTID ARTERY REVASCULARIZATION INTRAVASCULAR BRACHYTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. ENDOVASCULAR TREATMENT DEVICES MARKET FOR THROMBOLYSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. ENDOVASCULAR TREATMENT DEVICES MARKET FOR RENAL ARTERY ANGIOPLASTY AND STENTING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. ENDOVASCULAR TREATMENT DEVICES MARKET FOR TRANSFEMORAL CAROTID ARTERY STENTING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. ENDOVASCULAR TREATMENT DEVICES MARKET FOR TRANSCAROTID ARTERY REVASCULARIZATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. ENDOVASCULAR TREATMENT DEVICES MARKET FOR INTRAVASCULAR BRACHYTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. ENDOVASCULAR TREATMENT DEVICES MARKET FOR CAROTID ARTERY STENTING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. ENDOVASCULAR TREATMENT DEVICES MARKET SEGMENTATION, BY BY APPICATION
  • FIGURE 29. ENDOVASCULAR TREATMENT DEVICES MARKET FOR PULMONARY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. ENDOVASCULAR TREATMENT DEVICES MARKET FOR VASCULAR, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. ENDOVASCULAR TREATMENT DEVICES MARKET FOR CARDIOLOGY SURGERY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 32. ENDOVASCULAR TREATMENT DEVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 33. ENDOVASCULAR TREATMENT DEVICES MARKET FOR RADIOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 34. ENDOVASCULAR TREATMENT DEVICES MARKET SEGMENTATION, BY BY END USER
  • FIGURE 35. ENDOVASCULAR TREATMENT DEVICES MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 36. ENDOVASCULAR TREATMENT DEVICES MARKET FOR AMBULATORY SURGICAL CENTER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 37. ENDOVASCULAR TREATMENT DEVICES MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 38. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 42. COMPETITIVE DASHBOARD
  • FIGURE 43. COMPETITIVE HEATMAP: ENDOVASCULAR TREATMENT DEVICES MARKET
  • FIGURE 44. TOP PLAYER POSITIONING, 2024
  • FIGURE 45. CARDINAL HEALTH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. CARDINAL HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. CARDINAL HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. ENDOSPAN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. ENDOSPAN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. ENDOSPAN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. GETINGE AB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. GETINGE AB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. GETINGE AB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. INSPIREMD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. INSPIREMD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. INSPIREMD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. JAPAN LIFELINE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. JAPAN LIFELINE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. JAPAN LIFELINE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 63. MEDTRONIC PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 64. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 65. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 66. LOMBARD MEDICAL TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 67. LOMBARD MEDICAL TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 68. LOMBARD MEDICAL TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 69. PENUMBRA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 70. PENUMBRA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 71. PENUMBRA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 72. TERUMO CORPORATION.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 73. TERUMO CORPORATION.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 74. TERUMO CORPORATION.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Endovascular Treatment Devices Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue